Log In Get Started
Press Releases March 30, 2026

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference

InspireMD to present at the 25th Annual Needham Virtual Healthcare Conference

By Leila Farooq NSPR
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
NSPR

InspireMD, Inc., developer of the CGuard Prime carotid stent system, announced its participation in the 25th Annual Needham Virtual Healthcare Conference with a presentation scheduled for April 14th. The event will be webcast live and archived on InspireMD's corporate website.

Key Points

  • InspireMD will present at a prominent healthcare investment conference, increasing its visibility among investors.
  • The company focuses on its proprietary MicroNet mesh technology aimed at improving carotid stenting outcomes to prevent strokes.
  • The presentation includes live audio webcast and online archive, facilitating broad investor access.

MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 12:45 pm Eastern Time (ET).

A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Investor Contacts:
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com


Risks

  • Market response to the conference presentation is uncertain, and no new clinical or financial data is indicated in the announcement.
  • The success of InspireMD's proprietary technology depends on clinical adoption and regulatory factors in the medical devices sector.
  • Competition in the carotid stent and stroke prevention market could impact InspireMD's market share and growth potential.

More from Press Releases

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders Apr 3, 2026 Midland States Bancorp, Inc. To Announce First Quarter 2026 Financial Results On Thursday, April 23 Apr 3, 2026 Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 3, 2026 Multi-Sensor Data Labeling and AI Data Operations: What Enterprise AV Teams Apr 3, 2026 Wix Announces Final Results of Modified Dutch Auction Tender Offer Apr 3, 2026